Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge
Objective To describe age‐specific prostate‐specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population‐wide opportunistic PSA testing. Patients and Methods Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During...
Uloženo v:
| Vydáno v: | BJU international Ročník 133; číslo 1; s. 104 - 111 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Wiley Subscription Services, Inc
01.01.2024
|
| Témata: | |
| ISSN: | 1464-4096, 1464-410X, 1464-410X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Objective
To describe age‐specific prostate‐specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population‐wide opportunistic PSA testing.
Patients and Methods
Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age‐specific PSA value distributions were constructed for men aged 45–75 years with and without prostate cancer.
Results
The distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10‐fold from the age of 45 to 75 years. PSA testing identified intermediate‐ or high‐grade cancers in 21% (95% confidence interval [CI] 19–23%) of men aged 50–54 years and 42% (95% CI 41–43%) of men aged 70–74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50–54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70–74 years.
Conclusion
Opportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years. |
|---|---|
| AbstractList | ObjectiveTo describe age‐specific prostate‐specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population‐wide opportunistic PSA testing.Patients and MethodsOver 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age‐specific PSA value distributions were constructed for men aged 45–75 years with and without prostate cancer.ResultsThe distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10‐fold from the age of 45 to 75 years. PSA testing identified intermediate‐ or high‐grade cancers in 21% (95% confidence interval [CI] 19–23%) of men aged 50–54 years and 42% (95% CI 41–43%) of men aged 70–74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50–54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70–74 years.ConclusionOpportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years. To describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide opportunistic PSA testing.OBJECTIVETo describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide opportunistic PSA testing.Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age-specific PSA value distributions were constructed for men aged 45-75 years with and without prostate cancer.PATIENTS AND METHODSOver 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age-specific PSA value distributions were constructed for men aged 45-75 years with and without prostate cancer.The distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10-fold from the age of 45 to 75 years. PSA testing identified intermediate- or high-grade cancers in 21% (95% confidence interval [CI] 19-23%) of men aged 50-54 years and 42% (95% CI 41-43%) of men aged 70-74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50-54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70-74 years.RESULTSThe distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10-fold from the age of 45 to 75 years. PSA testing identified intermediate- or high-grade cancers in 21% (95% confidence interval [CI] 19-23%) of men aged 50-54 years and 42% (95% CI 41-43%) of men aged 70-74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50-54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70-74 years.Opportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years.CONCLUSIONOpportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years. To describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide opportunistic PSA testing. Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age-specific PSA value distributions were constructed for men aged 45-75 years with and without prostate cancer. The distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10-fold from the age of 45 to 75 years. PSA testing identified intermediate- or high-grade cancers in 21% (95% confidence interval [CI] 19-23%) of men aged 50-54 years and 42% (95% CI 41-43%) of men aged 70-74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50-54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70-74 years. Opportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years. Objective To describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide opportunistic PSA testing.Patients and Methods Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age-specific PSA value distributions were constructed for men aged 45-75 years with and without prostate cancer.Results The distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10-fold from the age of 45 to 75 years. PSA testing identified intermediate- or high-grade cancers in 21% (95% confidence interval [CI] 19-23%) of men aged 50-54 years and 42% (95% CI 41-43%) of men aged 70-74 years. Grade group (GG)1, GG2, GG3 and >= GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50-54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70-74 years.Conclusion Opportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged >= 70 years. Objective To describe age‐specific prostate‐specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population‐wide opportunistic PSA testing. Patients and Methods Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age‐specific PSA value distributions were constructed for men aged 45–75 years with and without prostate cancer. Results The distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10‐fold from the age of 45 to 75 years. PSA testing identified intermediate‐ or high‐grade cancers in 21% (95% confidence interval [CI] 19–23%) of men aged 50–54 years and 42% (95% CI 41–43%) of men aged 70–74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50–54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70–74 years. Conclusion Opportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years. |
| Author | Fosså, Sophie Pasovic, Lara Müller, Stig Albertsen, Peter C. Carlsson, Sigrid V. Oldenburg, Jan Bjerner, Lars Johan |
| AuthorAffiliation | 3 Department of Urology, Akershus University Hospital, Lørenskog, Norway 4 Medical Faculty, University of Oslo, Oslo, Norway 1 Department of Surgery (Urology), UConn Health, Farmington, CT, USA 2 Fürst Laboratories, Department of Clinical Chemistry, Oslo, Norway 6 Department of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA 5 Oslo University Hospital Department of Oncology 7 Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden 8 Department of Oncology, Akershus University Hospital, Lørenskog, Norway |
| AuthorAffiliation_xml | – name: 3 Department of Urology, Akershus University Hospital, Lørenskog, Norway – name: 2 Fürst Laboratories, Department of Clinical Chemistry, Oslo, Norway – name: 5 Oslo University Hospital Department of Oncology – name: 8 Department of Oncology, Akershus University Hospital, Lørenskog, Norway – name: 1 Department of Surgery (Urology), UConn Health, Farmington, CT, USA – name: 4 Medical Faculty, University of Oslo, Oslo, Norway – name: 6 Department of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA – name: 7 Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden |
| Author_xml | – sequence: 1 givenname: Peter C. surname: Albertsen fullname: Albertsen, Peter C. email: albertsen@uchc.edu organization: UConn Health – sequence: 2 givenname: Lars Johan surname: Bjerner fullname: Bjerner, Lars Johan organization: Fürst Laboratories – sequence: 3 givenname: Lara surname: Pasovic fullname: Pasovic, Lara organization: Akershus University Hospital – sequence: 4 givenname: Stig surname: Müller fullname: Müller, Stig organization: University of Oslo – sequence: 5 givenname: Sophie surname: Fosså fullname: Fosså, Sophie organization: Oslo University Hospital – sequence: 6 givenname: Sigrid V. surname: Carlsson fullname: Carlsson, Sigrid V. organization: Sahlgrenska Academy at Gothenburg University – sequence: 7 givenname: Jan surname: Oldenburg fullname: Oldenburg, Jan organization: Akershus University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37869764$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/331991$$DView record from Swedish Publication Index (Göteborgs universitet) |
| BookMark | eNp1kstuFDEQRS2UiDxgwQ-gltiQRSd-9MPNBkFECCgiGyKxQZbbU-7xyGN32t0ZZccn8I18SSrMDCIReGPr-tTVVVUdkJ0QAxDygtFjhuekXUzHrOKMPSH7rKiKvGD02872TZtqjxyktKAUhap8SvZELaumrop98v2y7-MwTsGl0ZmsH2Ia9Qi_fvxMPRhnUdNhdB2EbAREQpe5kH2Jwwo6p0O2hPAm01k_tR7ROWg_zjMz195D6OAZ2bXaJ3i-uQ_J1dmHr6fn-cXlx0-n7y5yU0jOcskb25aspLa2dc3KtoJqZqwUJUOZttAaAVRozmtRWmvqsm0ZnTWaM0NracUhyde-aQUYRfWDW-rhVkXtVDf1CqVuUgmUEKxpGPJv1zzCS5gZCOOg_YOyhz_BzVUXbxSjsuBMSnR4vXEY4vWEnVFLlwx4rwPEKSkuJZW84AVF9NUjdBGnIWA_FG-ooGVZFwKpl39H-pNlOyoETtaAwRmlAawyDkfl4n1C5zGaul8Ghcugfi8DVhw9qtia_ovduK-ch9v_g-r956t1xR10j8YK |
| CitedBy_id | crossref_primary_10_1016_j_eururo_2024_08_034 crossref_primary_10_1016_j_ejso_2025_109688 crossref_primary_10_1016_j_ejon_2024_102658 crossref_primary_10_1016_j_eururo_2024_05_023 crossref_primary_10_1111_bju_16357 crossref_primary_10_1093_ije_dyaf082 crossref_primary_10_1111_bju_16356 crossref_primary_10_1038_s41391_025_00989_2 crossref_primary_10_2340_1651_226X_2024_32953 |
| Cites_doi | 10.1001/jama.2018.0154 10.1001/jama.1993.03510070082041 10.1056/NEJMoa1807801 10.1056/NEJM199104253241702 10.1056/NEJMoa2214122 10.1016/j.euf.2022.06.008 10.1016/j.eururo.2021.07.024 10.1056/NEJMms1914228 10.1001/jama.2018.3710 10.1001/jamanetworkopen.2022.43449 10.1016/j.eururo.2014.12.006 10.1515/cclm-2019-0693 10.1001/jama.289.20.2695 10.1056/NEJMoa2209454 10.1056/NEJM198710083171501 10.1056/NEJMoa1801993 10.7326/0003-4819-157-2-201207170-00459 10.1056/NEJMe0901166 10.1056/NEJMoa0810084 10.1016/j.eururo.2023.04.028 10.1001/jama.1995.03530150038031 10.1038/s41391-020-0227-1 10.1016/j.eururo.2019.10.030 10.1056/NEJMoa1615869 10.1001/jama.1992.03480160073037 10.1056/NEJMoa031918 10.1111/bju.15859 10.1001/jamanetworkopen.2023.1439 |
| ContentType | Journal Article |
| Copyright | 2023 BJU International. Copyright © 2024 BJU International |
| Copyright_xml | – notice: 2023 BJU International. – notice: Copyright © 2024 BJU International |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7X8 5PM ADTPV AOWAS F1U |
| DOI | 10.1111/bju.16211 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Göteborgs universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1464-410X |
| EndPage | 111 |
| ExternalDocumentID | oai_gup_ub_gu_se_331991 PMC10842188 37869764 10_1111_bju_16211 BJU16211 |
| Genre | researchArticle Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: K22 CA234400 – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X CGR CUY CVF ECM EIF NPM 7QP 7X8 5PM ADTPV AOWAS F1U |
| ID | FETCH-LOGICAL-c4821-829fb5150f7f7715b6e6dcf8351b510bebc3e03a22735ffc75bb10d9a21c078f3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001097558100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Tue Nov 04 17:03:56 EST 2025 Tue Nov 04 02:04:38 EST 2025 Wed Oct 01 10:44:56 EDT 2025 Tue Oct 07 06:47:04 EDT 2025 Mon Jul 21 06:03:47 EDT 2025 Sat Nov 29 06:59:02 EST 2025 Tue Nov 18 21:18:11 EST 2025 Wed Jan 22 16:19:22 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | prostate cancer cancer screening prostate cancer mortality public health PSA |
| Language | English |
| License | 2023 BJU International. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4821-829fb5150f7f7715b6e6dcf8351b510bebc3e03a22735ffc75bb10d9a21c078f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://pmc.ncbi.nlm.nih.gov/articles/PMC10842188/pdf/nihms-1939042.pdf |
| PMID | 37869764 |
| PQID | 2903055743 |
| PQPubID | 1026371 |
| PageCount | 111 |
| ParticipantIDs | swepub_primary_oai_gup_ub_gu_se_331991 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10842188 proquest_miscellaneous_2880824240 proquest_journals_2903055743 pubmed_primary_37869764 crossref_citationtrail_10_1111_bju_16211 crossref_primary_10_1111_bju_16211 wiley_primary_10_1111_bju_16211_BJU16211 |
| PublicationCentury | 2000 |
| PublicationDate | January 2024 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: January 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2024 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2021; 24 2012; 2012 2020; 382 2023; 6 2023; 388 1992; 267 2020; 58 2020; 77 1995; 274 2017; 377 2015; 68 2022; 387 2012; 157 2023 2023; 131 2022; 5 2004; 350 2022; 8 2018; 379 1987; 317 2018; 378 1993; 270 2018; 319 2009; 360 2003; 289 1991; 324 2021; 80 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 Casey RG (e_1_2_9_30_1) 2012; 2012 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 38553875 - BJU Int. 2024 Aug;134(2):314. doi: 10.1111/bju.16356. |
| References_xml | – volume: 317 start-page: 909 year: 1987 end-page: 916 article-title: Prostate‐specific antigen as a serum marker for adenocarcinoma of the prostate publication-title: N Engl J Med – volume: 274 start-page: 1214 year: 1995 end-page: 1220 article-title: Evaluation of percentage of free serum prostate‐specific antigen to improve specificity of prostate cancer screening publication-title: JAMA – volume: 80 start-page: 703 year: 2021 end-page: 711 article-title: Prostate‐specific antigen testing as part of a risk‐adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021 publication-title: Eur Urol – volume: 360 start-page: 1351 year: 2009 end-page: 1354 article-title: Screening for prostate cancer – the controversy that refuses to die publication-title: N Engl J Med – volume: 382 start-page: 1557 year: 2020 end-page: 1563 article-title: Reconsidering prostate cancer mortality – the future of PSA screening publication-title: N Engl J Med – volume: 388 start-page: 1547 year: 2023 end-page: 1558 article-title: 15 year outcomes after monitoring, surgery or radiotherapy for localized prostate cancer publication-title: N Engl J Med – volume: 378 start-page: 1767 year: 2018 end-page: 1777 article-title: MRI‐targeted or standard biopsy for prostate‐cancer diagnosis publication-title: N Engl J Med – volume: 5 year: 2022 article-title: Low‐value prostate‐specific antigen test for prostate cancer screening and subsequent health care utilization and spending publication-title: JAMA Netw Open – volume: 324 start-page: 1156 year: 1991 end-page: 1161 article-title: Measurement of prostate‐specific antigen in serum as a screening test for prostate cancer publication-title: N Engl J Med – volume: 68 start-page: 354 year: 2015 end-page: 360 article-title: Opportunistic testing versus organized prostate‐specific antigen screening: outcome after 18 years in the Göteborg randomized population‐based prostate cancer screening trial publication-title: Eur Urol – volume: 319 start-page: 1901 year: 2018 end-page: 1913 article-title: Screening for prostate cancer. US Preventive Services Task force recommendation statement publication-title: JAMA – year: 2023 article-title: Baseline serum prostate‐specific antigen value predicts the risk of subsequent prostate cancer death: results from the Norwegian prostate cancer consortium publication-title: Eur Urol – volume: 77 start-page: 320 year: 2020 end-page: 330 article-title: Ten‐year mortality, disease progression and treatment related side effects in men with localized prostate cancer from the ProtecT randomized controlled trial according to treatment received publication-title: Eur Urol – volume: 289 start-page: 2695 year: 2003 end-page: 2700 article-title: Variation of serum prostate specific antigen levels: an evaluation of year‐to‐year fluctuations publication-title: JAMA – volume: 387 start-page: 2126 year: 2022 end-page: 2137 article-title: Prostate cancer screening with PSA and MRI followed by targeted biopsy only publication-title: N Engl J Med – volume: 8 start-page: 1568 year: 2022 end-page: 1574 article-title: Designing and implementing a population based organized prostate cancer testing programme publication-title: Eur Urol Focus – volume: 131 start-page: 130 year: 2023 end-page: 131 article-title: Age‐related PSA testing for prostate cancer: NICE recommendation 1.6.3 publication-title: BJU Int – volume: 350 start-page: 2239 year: 2004 end-page: 2246 article-title: Prevalence of prostate cancer among men with a prostate‐specific antigen level ≤4.0 ng per milliliter publication-title: N Engl J Med – volume: 377 start-page: 132 year: 2017 end-page: 142 article-title: Follow‐up of prostatectomy versus observation for early prostate cancer publication-title: N Engl J Med – volume: 6 year: 2023 article-title: Time trends and variation in the use of active surveillance for the management of low risk prostate cancer in the US publication-title: JAMA Netw Open – volume: 157 start-page: 120 year: 2012 end-page: 134 article-title: Screening for prostate cancer: US preventive task force recommendation statement publication-title: Ann Intern Med – volume: 24 start-page: 77 year: 2021 end-page: 80 article-title: Shared decision making and prostate‐specific antigen based prostate cancer screening following the 2018 update of the USPSTF screening guideline publication-title: Prostate Cancer Prostatic Dis – volume: 58 start-page: 326 year: 2020 end-page: 339 article-title: Biomarkers for prostate cancer: prostate‐specific antigen and beyond publication-title: Clin Chem Lab Med – volume: 270 start-page: 860 year: 1993 end-page: 864 article-title: Serum prostate‐specific antigen in community‐based population of healthy men: establishment of age‐specific reference ranges publication-title: JAMA – volume: 360 start-page: 1320 year: 2009 end-page: 1328 article-title: Screening and prostate cancer mortality in a randomized European study publication-title: N Engl J Med – volume: 2012 year: 2012 article-title: The distribution of PSA age‐specific profiles in healthy Irish men between age 20 and 70 publication-title: ISRN Oncol – volume: 379 start-page: 2319 year: 2018 end-page: 2329 article-title: Radical prostatectomy or watchful waiting in prostate cancer – 29 year follow up publication-title: N Engl J Med – volume: 267 start-page: 2215 year: 1992 end-page: 2220 article-title: Longitudinal evaluation of prostate‐specific antigen levels in men with and without prostate disease publication-title: JAMA – volume: 319 start-page: 883 year: 2018 end-page: 895 article-title: Effect of a low‐intensity PSA‐based screening intervention on prostate cancer mortality: the CAP randomized clinical trial publication-title: JAMA – ident: e_1_2_9_13_1 doi: 10.1001/jama.2018.0154 – ident: e_1_2_9_10_1 doi: 10.1001/jama.1993.03510070082041 – ident: e_1_2_9_26_1 doi: 10.1056/NEJMoa1807801 – ident: e_1_2_9_3_1 doi: 10.1056/NEJM199104253241702 – ident: e_1_2_9_25_1 doi: 10.1056/NEJMoa2214122 – ident: e_1_2_9_22_1 doi: 10.1016/j.euf.2022.06.008 – ident: e_1_2_9_21_1 doi: 10.1016/j.eururo.2021.07.024 – ident: e_1_2_9_20_1 doi: 10.1056/NEJMms1914228 – ident: e_1_2_9_6_1 doi: 10.1001/jama.2018.3710 – volume: 2012 year: 2012 ident: e_1_2_9_30_1 article-title: The distribution of PSA age‐specific profiles in healthy Irish men between age 20 and 70 publication-title: ISRN Oncol – ident: e_1_2_9_24_1 doi: 10.1001/jamanetworkopen.2022.43449 – ident: e_1_2_9_8_1 doi: 10.1016/j.eururo.2014.12.006 – ident: e_1_2_9_17_1 doi: 10.1515/cclm-2019-0693 – ident: e_1_2_9_11_1 doi: 10.1001/jama.289.20.2695 – ident: e_1_2_9_19_1 doi: 10.1056/NEJMoa2209454 – ident: e_1_2_9_2_1 doi: 10.1056/NEJM198710083171501 – ident: e_1_2_9_18_1 doi: 10.1056/NEJMoa1801993 – ident: e_1_2_9_5_1 doi: 10.7326/0003-4819-157-2-201207170-00459 – ident: e_1_2_9_4_1 doi: 10.1056/NEJMe0901166 – ident: e_1_2_9_14_1 doi: 10.1056/NEJMoa0810084 – ident: e_1_2_9_15_1 doi: 10.1016/j.eururo.2023.04.028 – ident: e_1_2_9_16_1 doi: 10.1001/jama.1995.03530150038031 – ident: e_1_2_9_7_1 doi: 10.1038/s41391-020-0227-1 – ident: e_1_2_9_28_1 doi: 10.1016/j.eururo.2019.10.030 – ident: e_1_2_9_27_1 doi: 10.1056/NEJMoa1615869 – ident: e_1_2_9_9_1 doi: 10.1001/jama.1992.03480160073037 – ident: e_1_2_9_12_1 doi: 10.1056/NEJMoa031918 – ident: e_1_2_9_23_1 doi: 10.1111/bju.15859 – ident: e_1_2_9_29_1 doi: 10.1001/jamanetworkopen.2023.1439 – reference: 38553875 - BJU Int. 2024 Aug;134(2):314. doi: 10.1111/bju.16356. |
| SSID | ssj0014665 |
| Score | 2.4773874 |
| Snippet | Objective
To describe age‐specific prostate‐specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population‐wide... To describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide opportunistic... ObjectiveTo describe age‐specific prostate‐specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population‐wide... Objective To describe age-specific prostate-specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population-wide... |
| SourceID | swepub pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 104 |
| SubjectTerms | Age Aged Aging Antigens Biopsy cancer mortality cancer screening Humans Male Mass Screening Medical diagnosis Middle Aged Nephrology Njurmedicin population Prostate cancer prostate cancer mortality Prostate-Specific Antigen Prostatic Neoplasms - diagnosis Prostatic Neoplasms - epidemiology PSA Public Health serum Urology & Nephrology |
| Title | Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbju.16211 https://www.ncbi.nlm.nih.gov/pubmed/37869764 https://www.proquest.com/docview/2903055743 https://www.proquest.com/docview/2880824240 https://pubmed.ncbi.nlm.nih.gov/PMC10842188 https://gup.ub.gu.se/publication/331991 |
| Volume | 133 |
| WOSCitedRecordID | wos001097558100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1464-410X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014665 issn: 1464-4096 databaseCode: DRFUL dateStart: 19990101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ti9QwEB7OPRFBfDnfqucRRQ6_VNq0TVP95NsioquIC_vlKE2a7u2h3WV3q1_9Cf5Gf4kzSVssdweCn1qaCSXJTPIkk3kG4LE2SawSUaDyFpGPiLhEk4qFjztmqbJSR3FQ2mQT6WQiZ7Ps0w4872JhHD9Ef-BGlmHnazLwQm3-MnJ10jwNBae43l2OepuMYPf15_H0fe9EiIXNJInPGLdJmWiJhegiT195uBydwpinr0q2hKJDLGsXo_G1_2rGdbjaYlD2winNDdgx9R5c-tB62ffgijvLYy5E6SYcfVwRSifHN9ZgKwoUQYj6--cvitOku0YMx4doPdmWSDvqOVvUbLJc_zBz1D72zdTPWMEcozZzkZdMd1lcbsF0_ObLq7d-m5bB17HkoS95VimEQUGVVmkaJkoYUeoKoVyInwNllI5MEBUckVFSVTpNlAqDMit4qBGQVNFtGNXL2twFVpIbWRQqw3kkTrmRBO9UpaQMhYqqzIMn3ejkuuUsp9QZX_Nu74Ldl9vu8-BRL7pyRB1nCe13Q5y3trrJeWZ50hBKefCwL0YrI9dJUZtlgzI4zUmKpAk8uOM0ov9LlEqBoC72QA50pRcgBu9hSb04tkzeYSBjxFjSg0OnVoM682aV46d5k29MHkV0SQ07xCrT-U3MX76b2pd7_y56Hy5zxGruZGkfRtt1Yx7ARf19u9isD-BCOpMHrXH9ARcHKJY |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bitRAEC2WXdEH8bJeNrpqKyK-RHLpdDrii7dh1dlRZAf2ZWnSnc7siGaGmYm--gl-o19iVeeCYRUEIZCQVBPSXdU5XdV1CuChsQnXichRefPYR0RcoElx4eOKWeqsMDEPCldsIp1M5PFx9mELnnW5MA0_RO9wI8tw8zUZODmkf7Ny_al-EoqIEnt3OKoR6vfOq4-j6biPInDhSknimeM6KRMtsxDt5OkbD_9HZ0Dm2b2SLaPoEMy6v9Ho8v99xxW41KJQ9rxRm6uwZatdOH_Yxtl34WLjzWNNktI1OHm_JJxOoW9swZaUKoIg9ef3H5SpSbuNGI4QEXuyDdF2VDM2r9hksfpmZ6h_7IutnrKcNZzarMm9ZKar43IdpqPXRy8P_LYwg2-4jEJfRlmpEQgFZVqmaZhoYUVhSgRzId4OtNUmtkGcR4iNkrI0aaJ1GBRZHoUGIUkZ34DtalHZPWAFBZJFrjOcSXgaWUkAT5daylDouMw8eNwNjzItazkVz_isutULdp9y3efBg1502VB1_Elovxtj1VrrWkWZY0pDMOXB_f4x2hkFT_LKLmqUwYlOUi5N4MHNRiX6t8SpFAjruAdyoCy9AHF4D59U81PH5R0GkiPKkh48avRq0GZWLxXemtVqbVUc0zY17BCnTX__RPXi7dRd3Pp30Xtw4eDocKzGbybvbpPvwjmZ8NiH7c2qtnfgnPm6ma9Xd1sb-wXChCuX |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtQwEB1V26pCQrSUSwMFDEKIl6BcHMdBvABlxaUsFWKlvlRW7NjbRZCNdjfw2k_gG_kSxnESERUkJJ4SxWNFtmfsY4_nDMBDpRMqE5aj8uaxj4i4QJOizMcdM5dZoWIaFE2yiXQy4Scn2fEGPOtiYRw_RH_gZi2jma-tgeuqML9ZufxcPwlZZAN7N6lNIjOCzcOP4-lR70WgrEkliU-K-6SMtcxC9iZPX3m4Hl0AmRfvSraMokMw26xG453_a8cuXGlRKHnu1OYqbOhyD7bft372PbjsTvOIC1K6BqcfKovTresba5DKhoogSP15_sNGatrbRgRHyBJ7krWl7ShnZF6SyWL5Xc9Q_8hXXT4lOXGc2sTFXhLV5XG5DtPxq08vX_ttYgZfUR6FPo8yIxEIBSY1aRomkmlWKINgLsTPgdRSxTqI8wixUWKMShMpw6DI8ihUCElMfANG5aLU-0AK60hmucxwJqFppLkFeNJIzkMmY5N58LgbHqFa1nKbPOOL6HYv2H2i6T4PHvSilaPq-JPQQTfGorXWlYiyhikNwZQH9_titDPrPMlLvahRBic6bmNpAg9uOpXo_xKnnCGsox7wgbL0ApbDe1hSzs8aLu8w4BRRFvfgkdOrQZ1ZXQn8NKvFSos4ttfUsEMabfp7E8WLt9Pm5da_i96D7ePDsTh6M3l3Gy5FCNzcMdMBjNbLWt-BLfVtPV8t77Ym9gsRQSsZ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Opportunistic+prostate-specific+antigen+testing+in+Norwegian+men%3A+a+public+health+challenge&rft.jtitle=BJU+international&rft.au=Albertsen%2C+Peter+C&rft.au=Bjerner%2C+Lars+Johan&rft.au=Pasovic%2C+Lara&rft.au=M%C3%BCller%2C+Stig&rft.date=2024-01-01&rft.eissn=1464-410X&rft.volume=133&rft.issue=1&rft.spage=104&rft_id=info:doi/10.1111%2Fbju.16211&rft_id=info%3Apmid%2F37869764&rft.externalDocID=37869764 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |